Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and Diabetes

INTRODUCTION: Sodium-glucose cotransporter-2 (SGLT2) inhibitors improve cardiovascular and kidney outcomes through mechanisms that are incompletely understood. In this exploratory post-hoc analysis of the VERTIS RENAL trial, we report the association between the SGLT2 inhibitor, ertugliflozin, and m...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hongyan, Sridhar, Vikas S., Lovblom, Leif Erik, Lytvyn, Yuliya, Burger, Dylan, Burns, Kevin, Brinc, Davor, Lawler, Patrick R., Cherney, David Z.I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343791/
https://www.ncbi.nlm.nih.gov/pubmed/34386658
http://dx.doi.org/10.1016/j.ekir.2021.05.022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343791/
https://www.ncbi.nlm.nih.gov/pubmed/34386658
http://dx.doi.org/10.1016/j.ekir.2021.05.022

Ejemplares similares